Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 122 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Platinum Sensitive Clear all
Completed Phase 2 Interventional

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

NCT04080284
View directory record Official record
Conditions
Endometrial Cancer, Papillary Serous Endometrial Carcinoma, Uterine Serous Carcinoma, Endometrial Carcinoma, Cancer of the Endometrium
Interventions
Niraparib
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
6
States / cities
New Brunswick, New Jersey • Newark, New Jersey • Bay Shore, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jul 21, 2026, 10:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

NCT01133756
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Lenvatinib, Carboplatin, Gemcitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

NCT02953457
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Olaparib, Tremelimumab
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 21, 2026, 10:20 PM EDT
Withdrawn Phase 1 Interventional

Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02050009
View directory record Official record
Conditions
Ovarian Papillary Serous Carcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer
Interventions
metformin hydrochloride, carboplatin, paclitaxel, laboratory biomarker analysis
Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer

NCT00719212
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
AMG 479
Biological
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
16
States / cities
Bakersfield, California • Fullerton, California • La Verne, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer

NCT01611558
View directory record Official record
Conditions
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Interventions
Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
17
States / cities
New Haven, Connecticut • Orlando, Florida • Tampa, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

NCT01281514
View directory record Official record
Conditions
Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
everolimus, carboplatin, pegylated liposomal doxorubicin hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

NCT01847274
View directory record Official record
Conditions
Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer
Interventions
Active comparator: Niraparib, placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Jul 21, 2026, 10:20 PM EDT
Terminated Phase 2 Interventional Results available

Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

NCT00582205
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
Interventions
Paclitaxel, Cisplatin IP
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

NCT03958045
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rucaparib and Nivolumab
Combination Product
Lead sponsor
Zhonglin Hao
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Jul 21, 2026, 10:20 PM EDT
Terminated Phase 4 Interventional Results available

Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment

NCT02035345
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Platinum Sensitive Ovarian Cancer
Interventions
Carboplatin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 1 Interventional

Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer

NCT03056833
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions
ribociclib, Paclitaxel, Carboplatin
Drug
Lead sponsor
Ronald Buckanovich
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Ann Arbor, Michigan • Bethel Park, Pennsylvania • Greensburg, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Jul 21, 2026, 10:20 PM EDT
Terminated Phase 1 Interventional

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03691376
View directory record Official record
Conditions
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
Interventions
Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cellular Therapy, Melphalan
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

NCT01995188
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Bevacizumab, Carboplatin, DNIB0600A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

NCT01188876
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
carboplatin, pralatrexate, Folic Acid, Vitamin B12 Injection
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 3 Interventional

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

NCT01204749
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions
AMG 386, AMG 386 Placebo, Paclitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
35
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

NCT01968213
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Rucaparib, Placebo
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Fullerton, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 1 Interventional

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT01459380
View directory record Official record
Conditions
Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
Bevacizumab, Carboplatin, Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride, Veliparib
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
13
States / cities
Aurora, Colorado • Augusta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

NCT00473954
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
EGEN-001 (phIL-12-005/PPC)
Genetic
Lead sponsor
EGEN, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Birmingham, Alabama • Huntsville, Alabama • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Jul 21, 2026, 10:20 PM EDT
Terminated Phase 3 Interventional

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

NCT01281254
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions
AMG386 plus PLD, Placebo plus PLD
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Norwalk, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 2 Interventional

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

NCT00466986
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Abraxane
Drug
Lead sponsor
Southeastern Gynecologic Oncology
Other
Eligibility
Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Jul 21, 2026, 10:20 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

NCT05231122
View directory record Official record
Conditions
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
Interventions
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Buffalo, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 2 Interventional

Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer

NCT00217568
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
pegfilgrastim, carboplatin, docetaxel
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Jul 21, 2026, 10:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

NCT02759588
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
Interventions
Olvi-Vec, Platinum-doublet with or without bevacizumab
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Newport Beach, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 10:20 PM EDT